Literature DB >> 25222653

Incident cases of primary Sjögren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics.

M Kvarnström1, V Ottosson, B Nordmark, M Wahren-Herlenius.   

Abstract

OBJECTIVES: To define the incidence rate of primary Sjögren's syndrome (pSS) and the prevalence of extraglandular manifestations (EGMs) at the time of diagnosis of pSS in a prospective, population-based manner.
METHOD: This study included all consecutive patients referred to the Department of Rheumatology at Karolinska University Hospital for the investigation of incident pSS from 1 January 2007 to 31 December 2011. Investigation was according to the current criteria for pSS, and examination with a focus on the presence of EGMs was performed.
RESULTS: Of the referred individuals, 199 out of 781 were diagnosed with pSS. We found an annual incidence rate of pSS in the Karolinska University Hospital catchment area of 3.1 [95% confidence interval (CI) 2.3-4.3] cases per 100 000 adult inhabitants. The female/male ratio of incident cases was 14/1 [frequency (female) = 0.93, 95% CI 0.89-0.96]. In our cohort, we noted lower figures for severe EGMs such as lung and neurological involvement than previously reported for prevalent pSS. The frequency of autoantibodies including antinuclear antibodies (ANA), anti-Ro/SSA, and anti-La/SSB was also lower compared to other cohorts. In our study, autoantibody-positive patients had cytopaenia significantly more often, and in patients older than 60 years primary biliary cirrhosis (PBC) was more common.
CONCLUSIONS: The incidence rate of pSS is 3.1 (95% CI 2.3-4.3) per 100 000 person-years. The prevalence of autoantibodies may be lower than previously reported, and at diagnosis, patients with pSS have few severe EGMs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25222653     DOI: 10.3109/03009742.2014.931457

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  20 in total

1.  Estimating the incidence of connective tissue diseases and vasculitides in a defined population in Northern Savo area in 2010.

Authors:  P Elfving; O Marjoniemi; H Niinisalo; A Kononoff; L Arstila; E Savolainen; J Rutanen; O Kaipiainen-Seppänen
Journal:  Rheumatol Int       Date:  2016-04-06       Impact factor: 2.631

2.  The rheumatic disease-associated FAM167A-BLK locus encodes DIORA-1, a novel disordered protein expressed highly in bronchial epithelium and alveolar macrophages.

Authors:  L Mentlein; G E Thorlacius; L Meneghel; L A Aqrawi; J I Ramírez Sepúlveda; J Grunewald; A Espinosa; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2018-05-16       Impact factor: 4.330

3.  Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort.

Authors:  Gabriel Maciel; Cynthia S Crowson; Eric L Matteson; Divi Cornec
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

4.  Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal).

Authors:  Virginia Fernandes Moça Trevisani; Alisson Pugliesi; Sandra Gofinet Pasoto; Maria Lucia Lemos Lopes; Lissiane Karine Noronha Guedes; Samira Tatiyama Miyamoto; Marilena Leal Mesquita Silvestre Fernandes; Sonia Cristina de Magalhães Souza Fialho; Aysa César Pinheiro; Laura Caldas Dos Santos; Simone Appenzeller; Tania Fidelix; Sandra Lúcia Euzébio Ribeiro; Danielle Christinne Soares Egypto de Brito; Tatiana Nayara Libório-Kimura; Maria Carmen Lopes Ferreira Silva Santos; Diego Ustárroz Cantali; Juliana D'Agostino Gennari; Vinicius Tassoni Civile; Ana Carolina Pereira Nunes Pinto; César Ramos Rocha-Filho; Fabiola Reis Oliveira; Aline Pereira da Rocha; Valeria Valim
Journal:  Adv Rheumatol       Date:  2022-06-01

5.  Clinical and laboratory evaluation of sicca complaints: distinctive aspects of primary, secondary and non-Sjogren syndrome.

Authors:  Fabíola Reis de Oliveira; Ana Carolina F Motta; Carolina Maria Módulo; Denny Marcos Garcia; John A Chiorini; Paulo Louzada-Junior; Eduardo Melani Rocha
Journal:  Adv Rheumatol       Date:  2022-07-01

6.  Association between a History of herpes zoster and the risk of Sjögren's syndrome: a nationwide, population-based, case-control study.

Authors:  Pei Ju Huang; Shih-Ping Lin; Chun-Yi Wu; Yen-Tze Liu; Hsin-Hua Chen
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

7.  Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome.

Authors:  Soledad Retamozo; Chiara Baldini; Hendrika Bootsma; Salvatore De Vita; Thomas Dörner; Benjamin A Fisher; Jacques-Eric Gottenberg; Gabriela Hernández-Molina; Agnes Kocher; Belchin Kostov; Aike A Kruize; Thomas Mandl; Wan-Fai Ng; Raphaèle Seror; Yehuda Shoenfeld; Antoni Sisó-Almirall; Athanasios G Tzioufas; Arjan Vissink; Claudio Vitali; Simon J Bowman; Xavier Mariette; Manuel Ramos-Casals; Pilar Brito-Zerón
Journal:  Drugs Aging       Date:  2021-02-23       Impact factor: 3.923

Review 8.  A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.

Authors:  Leanna M Wise; Daniel G Arkfeld
Journal:  Clin Rheumatol       Date:  2019-12-20       Impact factor: 2.980

9.  Primary Sjögren's Syndrome: A Retrospective Cohort Study of Burden of Illness in Sweden.

Authors:  Anna Westerlund; Anne Mette Tranberg Kejs; Heval Beydogan; Kerry Gairy
Journal:  Rheumatol Ther       Date:  2021-06-09

Review 10.  Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases.

Authors:  Thi Hong Van Le; Sang-Mo Kwon
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.